JP2010507093A - バイオマーカー - Google Patents

バイオマーカー Download PDF

Info

Publication number: JP2010507093A
Authority: JP; Japan
Prior art keywords: complement; pcos; haptoglobin; protein; sample
Prior art date: 2006-10-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2009532885A

Other languages

English (en)

Japanese (ja)

Inventor

ウィリアム・エイティオモ

ロバート・レイフィールド

キャサリン・ヒューズ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Nottingham

Original Assignee

University of Nottingham

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-16

Filing date

2007-10-15

Publication date

2010-03-04

2006-10-16 Priority claimed from GB0620467A external-priority patent/GB0620467D0/en

2007-04-26 Priority claimed from GB0708064A external-priority patent/GB0708064D0/en

2007-10-15 Application filed by University of Nottingham filed Critical University of Nottingham

2010-03-04 Publication of JP2010507093A publication Critical patent/JP2010507093A/ja

Status Pending legal-status Critical Current

Links

239000000090 biomarker Substances 0.000 title description 62
108090000623 proteins and genes Proteins 0.000 claims abstract description 175
102000004169 proteins and genes Human genes 0.000 claims abstract description 174
201000010065 polycystic ovary syndrome Diseases 0.000 claims abstract description 171
239000012634 fragment Substances 0.000 claims abstract description 80
239000002243 precursor Substances 0.000 claims abstract description 80
108010028778 Complement C4 Proteins 0.000 claims abstract description 56
102000014702 Haptoglobin Human genes 0.000 claims abstract description 56
108050005077 Haptoglobin Proteins 0.000 claims abstract description 56
238000000034 method Methods 0.000 claims abstract description 54
238000003776 cleavage reaction Methods 0.000 claims abstract description 43
230000007017 scission Effects 0.000 claims abstract description 43
239000000463 material Substances 0.000 claims abstract description 6
239000000523 sample Substances 0.000 claims description 80
108090000765 processed proteins & peptides Proteins 0.000 claims description 42
210000002966 serum Anatomy 0.000 claims description 31
150000002500 ions Chemical class 0.000 claims description 30
239000003153 chemical reaction reagent Substances 0.000 claims description 21
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 17
150000001875 compounds Chemical class 0.000 claims description 14
102000004196 processed proteins & peptides Human genes 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 11
238000001262 western blot Methods 0.000 claims description 11
102400000126 C4a anaphylatoxin Human genes 0.000 claims description 10
101800001547 C4a anaphylatoxin Proteins 0.000 claims description 10
102000004142 Trypsin Human genes 0.000 claims description 10
108090000631 Trypsin Proteins 0.000 claims description 10
239000012588 trypsin Substances 0.000 claims description 10
238000003745 diagnosis Methods 0.000 claims description 9
238000003018 immunoassay Methods 0.000 claims description 9
238000001155 isoelectric focusing Methods 0.000 claims description 8
238000003556 assay Methods 0.000 claims description 7
230000024203 complement activation Effects 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
230000002611 ovarian Effects 0.000 claims description 7
210000004369 blood Anatomy 0.000 claims description 6
239000008280 blood Substances 0.000 claims description 6
229920001184 polypeptide Polymers 0.000 claims description 6
210000001519 tissue Anatomy 0.000 claims description 6
238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 5
108020004707 nucleic acids Proteins 0.000 claims description 5
150000007523 nucleic acids Chemical class 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
238000003795 desorption Methods 0.000 claims description 4
238000000338 in vitro Methods 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
238000002493 microarray Methods 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 3
238000000018 DNA microarray Methods 0.000 claims description 2
238000000636 Northern blotting Methods 0.000 claims description 2
238000002105 Southern blotting Methods 0.000 claims description 2
210000000577 adipose tissue Anatomy 0.000 claims description 2
230000000692 anti-sense effect Effects 0.000 claims description 2
-1 antibodies Proteins 0.000 claims description 2
210000001124 body fluid Anatomy 0.000 claims description 2
239000010839 body fluid Substances 0.000 claims description 2
230000000052 comparative effect Effects 0.000 claims description 2
230000002357 endometrial effect Effects 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
230000002452 interceptive effect Effects 0.000 claims description 2
230000000116 mitigating effect Effects 0.000 claims description 2
210000002381 plasma Anatomy 0.000 claims description 2
230000020978 protein processing Effects 0.000 claims description 2
238000003757 reverse transcription PCR Methods 0.000 claims description 2
238000012216 screening Methods 0.000 claims description 2
238000004611 spectroscopical analysis Methods 0.000 claims description 2
210000002700 urine Anatomy 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 4
108010069112 Complement System Proteins Proteins 0.000 claims 1
102000000989 Complement System Proteins Human genes 0.000 claims 1
238000001502 gel electrophoresis Methods 0.000 claims 1
238000000386 microscopy Methods 0.000 claims 1
230000000295 complement effect Effects 0.000 abstract description 5
239000000499 gel Substances 0.000 description 51
238000004458 analytical method Methods 0.000 description 30
150000001413 amino acids Chemical group 0.000 description 27
238000012360 testing method Methods 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
239000013068 control sample Substances 0.000 description 14
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
102000009151 Luteinizing Hormone Human genes 0.000 description 11
108010073521 Luteinizing Hormone Proteins 0.000 description 11
229940040129 luteinizing hormone Drugs 0.000 description 11
238000013528 artificial neural network Methods 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
238000011002 quantification Methods 0.000 description 10
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
201000010099 disease Diseases 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
239000003098 androgen Substances 0.000 description 8
238000004949 mass spectrometry Methods 0.000 description 8
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
206010020112 Hirsutism Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 6
102100030758 Sex hormone-binding globulin Human genes 0.000 description 6
229940028334 follicle stimulating hormone Drugs 0.000 description 6
201000010066 hyperandrogenism Diseases 0.000 description 6
229960003604 testosterone Drugs 0.000 description 6
238000002604 ultrasonography Methods 0.000 description 6
108010029485 Protein Isoforms Proteins 0.000 description 5
102000001708 Protein Isoforms Human genes 0.000 description 5
230000008859 change Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
230000029087 digestion Effects 0.000 description 5
238000001962 electrophoresis Methods 0.000 description 5
230000027758 ovulation cycle Effects 0.000 description 5
239000012071 phase Substances 0.000 description 5
VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 5
238000004445 quantitative analysis Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
239000012146 running buffer Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000010200 validation analysis Methods 0.000 description 5
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
206010061818 Disease progression Diseases 0.000 description 4
206010022489 Insulin Resistance Diseases 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000000326 densiometry Methods 0.000 description 4
230000005750 disease progression Effects 0.000 description 4
238000010828 elution Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
238000012549 training Methods 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
101150057615 Syn gene Proteins 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229940027941 immunoglobulin g Drugs 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
239000000101 novel biomarker Substances 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 2
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 2
241001479434 Agfa Species 0.000 description 2
201000005670 Anovulation Diseases 0.000 description 2
206010002659 Anovulatory cycle Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102400000142 Haptoglobin alpha chain Human genes 0.000 description 2
101800000803 Haptoglobin alpha chain Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108700022034 Opsonin Proteins Proteins 0.000 description 2
206010036049 Polycystic ovaries Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010000496 acne Diseases 0.000 description 2
239000000959 ampholyte mixture Substances 0.000 description 2
229940030486 androgens Drugs 0.000 description 2
231100000552 anovulation Toxicity 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
229920003053 polystyrene-divinylbenzene Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 1
241000341965 Decodon <angiosperm> Species 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
102400000143 Haptoglobin beta chain Human genes 0.000 description 1
101800001341 Haptoglobin beta chain Proteins 0.000 description 1
101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
208000037093 Menstruation Disturbances Diseases 0.000 description 1
206010027339 Menstruation irregular Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000009328 Perro Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
108010026552 Proteome Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000364021 Tulsa Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
201000002996 androgenic alopecia Diseases 0.000 description 1
239000011324 bead Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000004154 complement system Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000010217 densitometric analysis Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000013101 initial test Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
238000005040 ion trap Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000011599 ovarian follicle development Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000001581 pretranslational effect Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
230000007026 protein scission Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
238000004451 qualitative analysis Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
239000012465 retentate Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000010206 sensitivity analysis Methods 0.000 description 1
150000003378 silver Chemical class 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000011537 solubilization buffer Substances 0.000 description 1
239000002594 sorbent Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000021510 thyroid gland disease Diseases 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000007738 vacuum evaporation Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000037221 weight management Effects 0.000 description 1

Images

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/361—Menstrual abnormalities or abnormal uterine bleeding, e.g. dysmenorrhea
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Bioinformatics & Computational Biology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Pathology (AREA)
Spectroscopy & Molecular Physics (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Optics & Photonics (AREA)
Biophysics (AREA)
Investigating Or Analysing Biological Materials (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

JP2009532885A 2006-10-16 2007-10-15 バイオマーカー Pending JP2010507093A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0620467A GB0620467D0 (en)	2006-10-16	2006-10-16	Biomarker
GB0708064A GB0708064D0 (en)	2007-04-26	2007-04-26	Biomarker
PCT/GB2007/003913 WO2008047086A2 (fr)	2006-10-16	2007-10-15	Biomarqueur

Publications (1)

Publication Number	Publication Date
JP2010507093A true JP2010507093A (ja)	2010-03-04

Family

ID=38834488

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009532885A Pending JP2010507093A (ja)	2006-10-16	2007-10-15	バイオマーカー

Country Status (3)

Country	Link
EP (1)	EP2076771A2 (fr)
JP (1)	JP2010507093A (fr)
WO (1)	WO2008047086A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014046045A1 (fr) *	2012-09-18	2014-03-27	国立大学法人鹿児島大学	Méthode de détection du vhc dans le sang, et procédé permettant de déterminer l'effet d'un traitement anti-vhc

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2153234A2 (fr)	2007-05-11	2010-02-17	The Institutes for Pharmaceutical Discovery, LLC	Procédé de diagnostic précoce de maladie rénale
WO2013079560A1 (fr)	2011-11-29	2013-06-06	Westfälische Wilhelms-Universität Münster	Marqueur génétique pour le syndrome des ovaires polykystiques (sopk)
CN106442764B (zh) *	2016-08-31	2019-01-22	王义明	多囊卵巢综合征的诊断和/或分型标志物及制备试剂的用途
CN111148844A (zh)	2017-09-01	2020-05-12	韦恩生物科技股份公司	鉴定和使用糖肽作为诊断和治疗监测的生物标记物

2007
- 2007-10-15 EP EP07824164A patent/EP2076771A2/fr not_active Withdrawn
- 2007-10-15 JP JP2009532885A patent/JP2010507093A/ja active Pending
- 2007-10-15 WO PCT/GB2007/003913 patent/WO2008047086A2/fr not_active Ceased

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014046045A1 (fr) *	2012-09-18	2014-03-27	国立大学法人鹿児島大学	Méthode de détection du vhc dans le sang, et procédé permettant de déterminer l'effet d'un traitement anti-vhc
JP2014059219A (ja) *	2012-09-18	2014-04-03	Kagoshima Univ	血中ｈｃｖ検出方法及び抗ｈｃｖ治療の効果判定方法

Also Published As

Publication number	Publication date
WO2008047086A3 (fr)	2008-07-17
WO2008047086A2 (fr)	2008-04-24
EP2076771A2 (fr)	2009-07-08

Publication	Publication Date	Title
US12422433B2 (en)	2025-09-23	Blood biomarker that predicts persistent cognitive dysfunction after concussion
Coon et al.	2008	CE‐MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics
US8389222B2 (en)	2013-03-05	Apolipoprotein fingerprinting technique and methods related thereto
CN110286234B (zh)	2023-03-24	尿液中妊娠糖尿病的蛋白质标志物及其在早期诊断中的用途
KR101850827B1 (ko)	2018-05-31	인지기능장애질환의 바이오 마커 및 당해 바이오 마커를 사용하는 인지기능장애질환의 검출방법
EP3260866B1 (fr)	2019-03-06	Nouveaux biomarqueurs de déficience cognitive et procédés permettant de détecter une déficience cognitive au moyen de tels biomarqueurs
US20180003724A1 (en)	2018-01-04	Alzheimer's disease diagnostic panels and methods for their use
CN105308455B (zh)	2019-04-09	用于诊断先兆子痫的方法和组合物
US8673644B2 (en)	2014-03-18	Serum markers for type II diabetes mellitus
JP2010507093A (ja)	2010-03-04	バイオマーカー
US20160018413A1 (en)	2016-01-21	Methods of Prognosing Preeclampsia
EP3654038B1 (fr)	2024-10-02	Biomarqueur pour troubles de type déficience cognitive et méthode de dépistage des troubles de type déficience cognitive à l'aide dudit biomarqueur
KR102475926B1 (ko)	2022-12-09	전신 홍반성 루푸스 진단용 바이오마커 조성물 및 이를 이용한 전신 홍반성 루푸스 진단에 필요한 정보를 제공하는 방법
KR102145438B1 (ko)	2020-08-18	퇴행성 뇌질환 발병 위험성 예측용 조성물 및 이를 이용한 퇴행성 뇌질환의 발병 위험성 예측 방법
WO2023120562A1 (fr)	2023-06-29	Dispositif, méthode et programme de calcul de diversité d'anticorps
KR20200099119A (ko)	2020-08-21	퇴행성 뇌질환 발병 위험성 예측용 조성물 및 이를 이용한 퇴행성 뇌질환의 발병 위험성 예측 방법